TY - JOUR
AU - Mehra, Mandeep R.
AB - Infiltration of the heart from insoluble protein deposits in amyloidosis often results in restrictive cardiomyopathy that manifests late in its course with heart failure and conduction abnormalities. While the rare primary amyloidosis–related heart disease has been well characterized, senile amyloidosis occurring in the seventh decade of life most frequently affects the heart. Early diagnosis of cardiac amyloidosis may improve outcomes but requires heightened suspicion and a systematic clinical approach to evaluation. Demonstration of tissue infiltration of biopsy specimens using special stains, followed by immunohistochemical studies and genetic testing, is essential in defining the specific protein involved. The therapeutic strategy depends on the characterization of the type of amyloid protein and extent of disease and may include chemotherapy, stem cell transplantation, and liver transplantation. Heart transplantation is controversial and is generally performed only at isolated centers.Matthias Schleiden, a German botanist and co-creator of the cell theory, fashioned the word amyloidin 1834 to describe the waxy starch in plants. Today, amyloidosis describes the infiltration of multiple organs by insoluble deposits composed of fibrillar protein that arise from a diverse group of disease processes. To date, 24 heterogeneous proteins prone to misfolding have been discovered that comprise amyloid deposits.The misfolded proteins arise secondary to genetic mutations or excess production and form a β-pleated sheet that aligns in an antiparallel manner. The sheets form insoluble amyloid fibrils that resist proteolysis and cause mechanical disruption and local oxidative stress in various organs.Regardless of which precursor protein causes disease, the deposits are virtually indistinguishable with light microscopy. The amorphous proteinacous substance stains pink with Congo red staining, with apple-green birefringence under polarizing light microscopy. The spectrum of organ involvement can include the kidneys, heart, blood vessels, central and peripheral nervous systems, liver, intestines, lungs, eyes, skin, and bones.Amyloid deposition in the heart is a devastating and progressive process that leads to congestive heart failure, angina, and arrhythmias. For patients with amyloidosis, infiltration of the heart confers the worst prognosis. In this systematic review, we discuss the clinical features of cardiac amyloidosis, present a diagnostic approach, and describe potential therapies.CLASSIFICATIONCardiac amyloidosis is classified by the protein precursor as primary, secondary (reactive), senile systemic, hereditary, isolated atrial, and hemodialysis-associated amyloidosis. These distinct forms are differentiated by means of immunohistochemical and genetic testing, and prognosis and therapeutic strategies differ among these subtypes (Table).Table. Classification of the Subtypes of Cardiac AmyloidosisAmyloidosis TypeProteinCardiac InvolvementMedian Survival, moExtracardiac ManifestationsDiagnostic TestingPrimary (AL)Light chain22%-34%13 (4 mo if heart failure present at diagnosis)Renal failure, proteinuria, hepatomegaly, autonomic dysfunction, macroglossia, purpura, neuropathy, carpal tunnel syndromeSPEP, UPEP,  bone marrow biopsy tissue analysis revealing plasma cell dyscrasia, κ and λ light-chain antiserum stainingHereditary (ATTR)Mutant TTRVariable70Severe neuropathy, autonomic dysfunction, renal failure, blindnessATTR antiserum staining, serum TTR isoelectric focusing, restriction fragment length polymorphism analysisSenile systemic (ATTR)TTRCommon75Diffuse organ involvementATTR antiserum stainingIsolated atrial (AANF)Atrial natriuretic factorLimited to heart. . .NoneAtrial natriuretic factor antiserum stainingReactive (AA)Amyloid A<10%24½Renal failure, proteinuria, hepatomegaly associated with chronic inflammatory conditionsTarget organ biopsy specimen analysis, AA antiserum stainingDialysis-related (β2-microglobulin)β2-MicroglobulinUnknown, asymptomatic. . .Arthralgias, carpal tunnel syndrome, arthropathies, bone cysts, pathologic fracturesSynovial and bone biopsy specimen analysis, β2-microglobulin antiserum, serum β2-microglobulin concentration Abbreviations: SPEP, serum protein electrophoresis; TTR, transthyretin; UPEP, urine protein electrophoresis.Primary AmyloidosisIn primary amyloidosis (AL), a plasma cell defect produces amyloidogenic immunoglobulin light-chain proteins, resulting in an aggressive form of amyloidosis. Primary amyloidosis is rare, with an incidence of 8.9 per million population.The mean survival has improved from 4.9 months in 1961 to 13.2 months in 1995.Primary amyloidosis affects more men than women (3:2), usually around the sixth decade of life.Cardiac involvement in AL is common, and 60% of patients demonstrate electrocardiographic or echocardiographic abnormalities. Clinical manifestations of heart failure identify a more aggressive natural history (median survival, 4 months). Death is attributed to cardiac causes in at least half of the patients with primary amyloidosis, who die of either heart failure or an arrhythmia.Light-chain amyloidosis affects several organs, and extracardiac manifestations often lead to the initial diagnosis. Early in the disease, nonspecific systemic complaints including weakness, fatigue, and weight loss dominate. Hepatomegaly results from infiltration of the liver or from hepatic congestion. Renal involvement causes profound proteinuria and nephrotic syndrome. Purpura and easy bruising, especially of the face and neck, occur from clotting factor deficiencies and fragile venules. Carpal tunnel syndrome, peripheral neuropathy, and macroglossia may also be present.Laboratory data reveal excess light-chain protein production. In one case series, 89% of patients with biopsy-confirmed primary amyloidosis had monoclonal light chains present at urine or serum protein immunofixation electrophoresis. The M protein type was primarily λ with a 2:1 predominance over κ. Bone marrow biopsy can reveal an increased fraction of plasma cells with proliferation of a clonal line and excessive λ and κ light-chain staining.Secondary AmyloidosisSecondary amyloidosis (AA) results from the accumulation of amyloid A fibrils formed from an acute-phase reactant, serum amyloid A protein. Secondary amyloidosis may be associated with rheumatoid arthritis, familial Mediterranean fever, chronic infections, and inflammatory bowel disease.Secondary amyloidosis of the heart is typically clinically insignificant.The primary pathologic findings involve the kidney, with development of proteinuria and renal failure. Treatment of the underlying process can reverse the disease.Senile Systemic AmyloidosisSenile systemic amyloidosis, an age-related disease, occurs in the aorta, heart tissue, brain, pancreas, lung, liver, kidney, and a number of other tissues.Wild-type transthyretin (TTR), a transport protein synthesized in the liver and choroid plexus, forms the amyloid deposits.Senile systemic amyloidosis affects men predominantly, usually after age 70 years, and affects the heart in 25% of persons older than 80 years.The disease is often unrecognized; however, extensive amyloid deposition leads to clinically significant heart failure. The disease course is less aggressive than AL, with a median survival of 75 months.Hereditary AmyloidosisHereditary (familial) amyloidosis is an autosomal dominant disease in which genetically mutated proteins form the amyloid fibrils. Mutations in both apolipoprotein I and TTR (ATTR) are known to lead to cardiac involvement, but our focus here is on TTR mutations, which are more prevalent.Variant forms of TTR caused by more than 80 point mutations in the DNA predispose the protein to misfolding and to amyloid formation.The prominent feature is peripheral and autonomic neuropathy, a clinical entity referred to as familial amyloid polyneuropathy. Mutations causing significant cardiac disease are methionine-for-valine substitution at position 30, serine-for-isoleucine substitution at position 84, and alanine-for-threonine substitution at position 60.While less aggressive than AL disease, ATTR-related cardiac amyloidosis also results in clinically significant heart failure.Familial amyloid polyneuropathy is generally classified by ancestral affiliation.Over years, patients develop progressive peripheral and autonomic neuropathy. Hyperesthesia to pain and temperature, motor weakness, and a diminished deep tendon reflex ascend from the lower extremities, and patients often become wheelchair dependent. Inactivity masks exertional symptoms from the underlying cardiomyopathy. Autonomic dysfunction includes impotence, decreased bowel motility, incontinence, and orthostatic hypotension.An isoleucine 122 gene mutation of the TTR DNA causes a familial amyloidosis primarily involving the heart without neurologic symptoms and is unique to elderly black persons. It is estimated that 1.3 million black persons are heterozygous for isoleucine 122.Presentation of the phenotype is variable, and the penetrance of the disease has yet to be defined.If tissue sampling confirms the presence of TTR in the amyloid deposits, isoelectric focusing of the patient's serum can differentiate mutant from normal TTR.Genetic testing by restriction fragment length polymorphism analysis can identify the type of mutation.Isolated Atrial AmyloidosisIsolated atrial amyloidosis (AANF) is composed of atrial natriuretic peptide, a protein secreted by atrial myocytes in response to increased wall stretch.The incidence of AANF increases with age (>90% in the ninth decade of life) and in females.The disease also occurs in young patients with valvular disease and in patients with chronic atrial fibrillation.AANF is limited to the heart as thin, linear deposits along and underneath the endocardium. It is unclear whether the disease process has any clinical significance.Hemodialysis-Related AmyloidosisPatients receiving long-term dialysis can develop cardiac amyloidosis with accumulation of β2-microglobulin from long-standing uremia.The protein accumulates with declining renal function and is ineffectively cleared with hemodialysis. The clinical effect of deposits occurring in the myocardium, pericardium, and cardiac valves is minimal, and the predominant symptoms are from joint involvement.Renal transplantation normalizes β2-microglobulin concentrations and improves joint pain.PATHOPHYSIOLOGYWhile several types of amyloid infiltrate the heart, only senile, hereditary, and primary amyloidosis commonly cause clinically significant disease. Amyloid infiltration of the heart interrupts contractile function and electrical conduction and influences coronary flow. Amyloid penetrates the myocardial interstitium in the form of nodular deposits and branching filaments interlacing individual myocytes. Early mild diastolic dysfunction can be noted at echocardiography, but late disease produces a thickened heart wall with a firm and rubbery consistency, worsening cardiac relaxation and compliance. The stiff heart wall elevates filling pressures, resulting in restrictive cardiomyopathy.Increased diastolic filling pressures lead to dilation of the atrial chambers. The less compliant left ventricle remains of normal chamber diameter with thickening of the free wall and septum.With progression, myocyte necrosis and local interstitial fibrosis result in systolic ventricular dysfunction. The deposition into the atrial walls is extensive and in rare cases can cause mechanical failure and conduction standstill.Endocardial deposition may cause valvular insufficiency and worsen congestive heart failure. In rare cases, pericardial involvement occurs with high-grade disease and can lead to constrictive physiologic findings.There are reports of pulmonary amyloid infiltration resulting in pulmonary hypertension and cor pulmonale.In addition to mechanical disruption, amyloid deposits induce oxidant stress that depresses myocyte contractile function.Amyloid also modulates interstitial matrix composition and tissue remodeling by disabling the balance of matrix metalloproteinases and their inhibitors.Myocardial ischemia results from microvasculature disease. Amyloid deposits spare the epicardial vessels, while involvement of the intramural vasculature is present in 90% of patients with AL amyloidosis.Although severe obstruction is rare, diffuse involvement leads to numerous endocardial foci of ischemia, microinfarction, and eventual fibrosis, contributing to further myocardial dysfunction.Direct invasion of the conduction system is rare. However, perivascular fibrosis secondary to microvascular ischemia commonly involves the sinus node and bundle of His.CLINICAL CHARACTERISTICSWhile systemic symptoms of amyloidosis are variable, cardiac findings are dominated by diastolic heart failure resulting from restrictive cardiomyopathy. Findings of right-sided heart failure predominate, including lower extremity edema, hepatomegaly, ascites, and elevated jugular pressure.A murmur may be present from valvular insufficiency, and atrial fibrillation is common.Anginal chest pain secondary to microvascular involvement with amyloid can also occur. Rare cases of amyloid manifesting as chest pain from intramural obstruction without evidence of myocardial deposition have been reported.Patients often have syncope and light-headedness resulting from autonomic dysfunction or arrhythmia in the setting of poor cardiac reserve. Amyloid deposition leads to obliteration of adrenergic input into the heart and alters baseline and compensatory neurohormonal cardiac stimulation.Often, autocorrection of hypertension is observed as relative hypotension develops.DIAGNOSISDiagnosis of amyloidosis must be established by histologic analysis of tissue. Congo red staining identifies amorphous pink deposits at light microscopy, which exhibit apple-green birefringence at examination under polarized microscopy (Figures 1, 2, and 3). If disease is limited to the heart, as in isoleucine 122 hereditary amyloidosis, examination of endomyocardial biopsy tissue is the only method of diagnosing the disease. Four endomyocardial biopsy samples ensure near 100% sensitivity for detecting disease.Less invasive tissue sampling methods are available for diagnosing systemic amyloid disease. The rectal submucosa has been the traditional biopsy site, with a reported sensitivity of 75% to 85%, but can be complicated by bleeding or perforation.Abdominal fat aspiration is without serious complications and is more sensitive (84%-88%) for diagnosing systemic amyloidosis.Endomyocardial biopsy specimens should be analyzed if less invasive methods fail to enable diagnosis of amyloidosis.Figure 1.View of myocardium at microscopy. The amorphous extracellular amyloid deposits (arrow) stain pink, and they disrupt the organization of the heart muscle (hemotoxylin-eosin, original magnification ×400).Figure 2.View of myocardium under polarizing microscopy. Amyloid infiltration of the myocardium (arrows) forms an apple-green birefringence under polarizing microscopy owing to the β-pleated fibrillar structure (Congo red stain, original magnification ×100).Figure 3.View of cardiac amyloidosis at electron microscopy. Note fibril mesh (arrow) within the myocardium (original magnification ×7500).Cardiac nonamyloidotic immunoglobulin deposition disease describes the nonfibrillary deposition of monoclonal immunoglobulin light chain in the setting of a plasma cell dyscrasia that mimics cardiac amyloidosis. Unlike amyloidosis, the biopsy specimen appears normal at microscopy with negative Congo red staining, and the disease usually improves with resolution of the blood disorder.CARDIAC BIOMARKERSSerum markers of cardiac injury or stress are often elevated in cardiac amyloidosis. Cardiac-specific troponin serum concentrations may rise because of myocyte necrosis from amyloid deposits and ischemia related to intramural vessel obstruction.Natriuretic peptide levels are also elevated secondary to elevated filling pressures and possibly myocyte necrosis.Elevations in the troponin and natriuretic peptide levels portend a poor prognosis; however, their usefulness in monitoring disease progression is unknown.ELECTROCARDIOGRAPHYLow-voltage QRS amplitudes in the precordial leads (≤10 mV in all leads) or limb leads (≤5 mV in all leads), a pseudoinfarction pattern (QS waves in consecutive leads), and conduction delays are common. The low-voltage amplitudes in relation to wall thickness result from the displacement of viable myocardium with amyloid deposits; however, they also occur in other conditions, including obesity, emphysema, hypothyroidism, effusion, myocardial fibrosis, and adrenal insufficiency.Dubrey et alreported that electrocardiograms for 75% of patients with cardiac amyloidosis demonstrated a pseudoinfarction pattern, and more than 70% exhibited low-voltage amplitudes. In another series, Murtagh et alchallenged these findings and found that only 47% of electrocardiograms demonstrated a pseudoinfarction pattern and that 46% exhibited low-voltage amplitudes. Numerous arrhythmias have been described, including atrial fibrillation, atrial flutter, ventricular tachycardia, atrioventricular block, prolonged QT interval, and junctional rhythm.ECHOCARDIOGRAPHYEchocardiography offers a noninvasive diagnostic approach for monitoring progression of disease. To our knowledge, Siqueira-Filho et alfirst described the “granular sparkling” refractile myocardium pathognomonic for the disease. Similar studies in patients with symptomatic disease revealed increased ventricular mass with thickening of the ventricular septal and free walls. Increasing wall thickness is inversely correlated with survival.Septal thickening can often imitate hypertrophic obstructive cardiomyopathy.Increased atrial septal wall thickening and granular sparkling myocardium are highly specific for differentiating cardiac amyloidosis from other causes of left ventricular hypertrophy.Both atria are typically dilated and the ventricular chamber dimensions are normal. Systolic function can be depressed with extensive disease.Doppler echocardiography provides useful information characterizing the progression of cardiac dysfunction. Early amyloid deposition impairs isovolumetric relaxation, resulting in decreased early diastolic flow velocity across the mitral valve (E) and increased dependence on atrial contraction for ventricular filling, leading to increased late diastolic filling velocities (A).The decreased E:A ratio of flow velocities is an earlier sign of amyloid involvement. As the heart wall becomes less compliant, left atrial pressures increase, as does early diastolic filling across the mitral valve, thus pseudonormalizing the E:A ratio.The echocardiographic findings of cardiac amyloidosis mimic other causes of left ventricular hypertrophy; thus, it is helpful to combine diagnostic methods to identify cardiac amyloidosis.Specifically, comparing the voltage on the electrocardiogram with the wall thickness on the echocardiogram can identify patients with infiltrative cardiomyopathy (Figure 4). Recent advances in echocardiography, including strain and strain rate Doppler imaging, may further improve the sensitivity of detecting cardiac amyloidosis.Figure 4.Approach to diagnosis of left ventricular hypertrophy. ECG indicates electrocardiogram.CARDIAC CATHETERIZATIONThe coronary angiogram is usually normal because only in rare cases does amyloid involve the epicardial vessels. Right-sided heart catheterization enables measurement of intracardiac pressures for diagnosis of restrictive cardiomyopathy. Characteristic findings on the hemodynamic profile of extensive amyloid deposition in the myocardium are indistinguishable from other causes of restrictive cardiomyopathy. Diastolic pressure is elevated in both ventricles and right-sided pressure tracings reveal a dip and plateau or square root sign.NUCLEAR SCINTIGRAPHYScintigraphic evaluation of the heart for uptake of radiolabeled phosphonates by amyloid was first explored more than 20 years ago.Sensitivity for diagnosis has been variable; thus, the test has not been incorporated into the routine workup for cardiac amyloidosis.A recent study, however, indicates that technetium Tc 99m–3,3,-diphosphono-1,2-propanodicarboxylic acid may be capable of differentiating TTR-associated amyloidosis from AL amyloidosis.CARDIAC MAGNETIC RESONANCE IMAGINGCardiac magnetic resonance imaging enables high-resolution 3-dimensional imaging of the myocardium and evaluation of chamber diameters, wall thickness and consistency, and regional wall motion.In addition, decreased tissue signal intensity along with late subendocardium tissue enhancement by gadolinium are a result of myocardial amyloid deposits and can help differentiate cardiac amyloidosis from other causes of cardiomyopathy.Figure 5shows the clinical and diagnostic findings that should raise suspicion for cardiac amyloidosis.Figure 5.Constellation of symptoms and signs and objective data suggestive of cardiac amyloidosis. CHF indicates congestive heart failure; SPEP, serum protein electrophoresis; and UPEP, urine protein electrophoresis.TREATMENTMedical TherapyThe primary goal of medical therapy is relief of symptoms, and decongestion is achieved by cautious diuresis. Orthostatic hypotension and obliteration of sympathetic input preclude use of negative inotropic agents. Reports describe clinical deterioration when cardiac amyloidosis is treated with calcium channel blockers.Similar reasoning extends to β-adrenergic receptor blockers, but this has not been demonstrated in the available literature. Digoxin binds to amyloid fibrils in vivo, and digoxin toxic effects have been reported.The binding properties of digoxin to amyloid deposits may disrupt safe administration of the medication. Patients should be instructed to monitor their weight and their fluid and salt intake daily.Use of DevicesPermanent pacemaker implantation is indicated in patients meeting guidelines for device placement.While cardiac pacing improves symptoms, it has not been shown to improve survival.No data are available on biventricular pacing or automatic implantable cardioverter-defibrillators in this population.Chemotherapy and Stem Cell TransplantationTreatment for AL includes oral chemotherapy (melphalan and prednisone) or high-dose chemotherapy with autologous stem cell transplantation. The benefit of oral chemotherapy is inadequate, and the greatest survival benefits are limited to patients without cardiac involvement.Stem cell transplantation has shown promising results for the treatment of primary amyloidosis.Compared with other hematologic malignancies, transplant-related mortality is increased 5-fold in amyloidosis. The increased mortality has been attributed to extensive and diffuse systemic end-organ damage from amyloid deposits, and patients with extensive cardiac disease are not optimal candidates for therapy.Solid Organ TransplantationHeart transplantation is not generally accepted as a viable treatment for cardiac amyloidosis because limited case series have suggested poor long-term survival as a result of disease recurrence in the allograft; however, extracardiac amyloid disease and sepsis are common modes of death.Adjuvant chemotherapy with transplantation has not been shown to improve mortality, but only limited data are available for modern regimens.Newer mechanical circulatory support ventricular assist devices may offer an alternative palliative therapy in end-stage heart failure as destination therapy, but no specific use of such devices in amyloidosis has been reported.Liver transplantation removes the source of mutant TTR and is the onlyknown curative treatment for hereditary amyloidosis. More than 500 patients with here ditary amyloidosis have undergone transplantation surgery.Five-year survival is reportedly 60% to 77%, with substantial improvement in neuropathy.If extensive cardiac infiltration is also present, combined heart and liver transplantation has been successfully performed in selected patients.Early identification of candidates for transplantation is critical because those with less severe manifestations of disease burden tolerate surgery better.SUMMARYCardiac amyloidosis is a rare disorder that poses a diagnostic challenge because its clinical characteristics overlap with common causes of cardiac disease. Heightened clinical suspicion coupled with classic findings, including low-voltage amplitudes on electrocardiograms and hyperrefractile myocardium on echocardiograms, typically help in the diagnosis of late-stage disease. While successful therapeutic interventions are limited, early diagnosis portends a better response to current therapy and prolonged survival. Thus, awareness and understanding of amyloidosis is important for cardiologists and general practitioners alike.Correspondence:Mandeep R. Mehra, MD, Division of Cardiology, University of Maryland, 22 S Greene St, Room S3BO6, Baltimore, MD 21201 (mmehra@medicine.umaryland.edu).Accepted for Publication:May 30, 2006.Financial Disclosure:None reported.Acknowledgment:We thank Allen Burke, MD, for providing the microscopy images.REFERENCESPWestermarkMDBensonJNBuxbaumAmyloid fibril protein nomenclature: 2002.Amyloid2002919720012408684GMerliniVBellottiMolecular mechanisms of amyloidosis.N Engl J Med200334958359612904524ASCohenAmyloidosis.N Engl J Med19672775225305340627RAKyleALinosCMBeardIncidence and natural history of primary systemic amyloidosis in Olmstead County, Minnesota, 1950 through 1989.Blood199279181718221558973RAKyleEDBayrd“Primary” systemic amyloidosis and myeloma: discussion of relationship and review of 81 cases.Arch Intern Med196110734435313755566RAKyleMAGertzPrimary systemic amyloidosis: clinical and laboratory features in 474 cases.Semin Hematol19953245597878478SWDubreyKChaJAndersonThe clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement.QJM1998911411579578896SWDubreyKChaRWSimmsMSkinnerRHFalkElectrocardiography and Doppler echocardiography in secondary (AA) amyloidosis.Am J Cardiol1996773133158607418MAGertzRAKyleSecondary systemic amyloidosis: response and survival in 64 patients.Medicine (Baltimore)1991702462562067409JDGillmoreLBLovatMRPerseyMBPepysPNHawkinsAmyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein.Lancet2001358242911454373PPitkanenPWestermarkGGCornwellIIISenile systemic amyloidosis.Am J Pathol19841173913996507586PWestermarkKSlettenBJohanssonGGCornwellIIIFibril in senile systemic amyloidosis is derived from normal transthyretin.Proc Natl Acad Sci U S A199087284328452320592GGCornwellIIIWLMurdochRAKylePWestermarkPPitkanenFrequency and distribution of senile cardiovascular amyloid: a clinicopathologic correlation.Am J Med1983756186236624768BNgLHConnorsRDavidoffMSkinnerRHFalkSenile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated (AL) amyloidosis.Arch Intern Med20051651425142915983293LHConnorsAMRichardsonRThebergeCECostelloTabulation of transthyretin (TTR) variants as of 1/1/2000.Amyloid20007546910842707DRJacobsonJNBuxbaumGenetic aspects of amyloidosis.Adv Hum Genet199120691231839349MDBensonMRWallaceETejadaHBaumannBPageHereditary amyloidosis: description of a new American kindred with late onset cardiomyopathy: Appalachian amyloid.Arthritis Rheum1987301952003030336DRJacobsonRPastoreSPoolRevised transthyretin Ile 122 allele frequency in African-Americans.Hum Genet1996982362388698351DRJacobsonDRPastoreRYaghoubianVariant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans.N Engl J Med19973364664739017939KAltlandABanzhoffSeparation by hybrid isoelectric focusing of normal human plasma transthyretin (prealbumin) and a variant with a methionine for valine substitution associated with familial amyloidotic polyneuropathy.Electrophoresis19867529533GCKayeMGButlerAJd’ArdenneSJEdmondsonAJCammGSlavinIsolated atrial amyloid contains atrial natriuretic peptide: a report of six cases.Br Heart J1986563173202945573BJohanssonCWernstedtPWestermarkAtrial natriuretic peptide deposited as atrial amyloid fibrils.Biochem Biophys Res Commun1987148108710922961331ERLevinDGGardnerWKSamsonNatriuretic peptides.N Engl J Med19983393213289682046SKawamuraMTakahashiTIshiharaFUchinoIncidence and distribution of isolated atrial amyloid: histologic and immunohistochemical studies of 100 aging hearts.Pathol Int1995453353427647929LMLooiIsolated atrial amyloidosis: a clinicopathologic study indicating increased prevalence in chronic heart disease.Hum Pathol1993246026078505038CRöckenBPetersGJuenemannAtrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation.Circulation20021062091209712379579OLeoneGBorianiBChiappiniAmyloid deposition as a cause of atrial remodelling in persistent valvular atrial fibrillation.Eur Heart J2004251237124115246642PWestermarkBJohanssonJBNatvigSenile cardiac amyloidosis: evidence of two different amyloid substances in the ageing heart.Scand J Immunol197910303308119309FGejyoTYamadaSOdaniA new form of amyloid protein associated with chronic hemodialysis was identified as beta 2-microglobulin.Biochem Biophys Res Commun19851297017063893430PDGorevicTTCaseyWJStoneCRDiRaimondoFCPrelliBFrangioneBeta-2 microglobulin is an amyloidogenic protein in man.J Clin Invest198576242524293908488LHNoelJZingraffTBardinCAtienzaDKuntzTDruekeTissue distribution of dialysis amyloidosis.Clin Nephrol1987271751783555909RGalAKorzetsASchwartzLRath-WolfsonUGafterSystemic distribution of beta 2-microglobulin-derived amyloidosis in patients who undergo long-term hemodialysis: report of seven cases and review of the literature.Arch Pathol Lab Med19941187187218024407SYTanAIrishCGWinearlsLong term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology.Kidney Int1996502822898807599CChewGMZiadyMJRaphaelCMOakleyThe functional defect in amyloid heart disease: the stiff heart syndrome.Am J Cardiol1975364384441190048RHSwantonIABrooksbyMJDaviesDJColtartBSJenkinsMMWebb-PeploeSystolic and diastolic ventricular function in cardiac amyloidosis: studies in six cases diagnosed with endomyocardial biopsy.Am J Cardiol197739658664857628TJSmithRAKyleJTLieClinical significance of histopathologic patterns of cardiac amyloidosis.Mayo Clin Proc1984595475556748745WCRobertsBFWallerCardiac amyloidosis causing cardiac dysfunction: analysis of 54 necropsy patients.Am J Cardiol1983521371466858901SMaedaTTanakaTHayashiFamilial atrial standstill caused by amyloidosis.Br Heart J1988594985003370185JFPlehnJSouthworthGGCornwellIIIBrief report: atrial systolic failure in primary amyloidosis.N Engl J Med1992327157015731435884DDingliJPUtzMAGertzPulmonary hypertension in patients with amyloidosis.Chest20011201735173811713162DABrennerMJainDRPimentelHuman amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress.Circ Res2004941008101015044325DMullerARoessnerCRockenDistribution pattern of matrix metalloproteinases 1, 2, 3, and 9, tissue inhibitors of matrix metalloproteinases 1 and 2, and α2-macroglobulin in cases of generalized AA- and AL amyloidosis.Virchows Arch200043752152711147173TBCrottyCYLiWDEdwardsVJSumanAmyloidosis and endomyocardial biopsy: correlation of extent and pattern of deposition with amyloid immunophenotype in 100 cases.Cardiovasc Pathol199543942RRSmithGMHutchinsIschemic heart disease secondary to amyloidosis of intramyocardial arteries.Am J Cardiol197944413417157693TNJamesPathology of the cardiac conduction system in amyloidosis.Ann Intern Med19666528365936665RLRidolfiBHBulkleyGMHutchinsThe conduction system in cardiac amyloidosis: clinical and pathologic features of 23 patients.Am J Med197762677686871125YIshikawaTIshiiSMasudaMyocardial ischemia due to vascular systemic amyloidosis: a quantitative analysis of autopsy findings on stenosis of the intramural coronary arteries.Pathol Int19964618919410846569SSchaferCSchardtUBurkhard-MeierRMKleinMPHeintzenBEStrauerAngina pectoris and progressive fatigue in a 61-year-old man.Circulation199694337633818989154JESaffitzKSazamaWCRobertsAmyloidosis limited to small arteries causing angina pectoris and sudden death.Am J Cardiol198351123412356837470RNarangPChopraHSWasirCardiac amyloidosis presenting as ischemic heart disease: a case report and review of literature.Cardiology1993822943008402756PSMuellerWDEdwardsMAGertzSymptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis.Am J Med200010918118810974179AVolpiACavalliAPMaggioniLMatturriLRossiCardiac amyloidosis involving the conduction system and the aortocoronary neuroreceptors: clinicopathologic correlates.Chest1986906196213757577PAPellikkaDRHolmesJrWDEdwardsRANishimuraAJTajikRAKyleEndomyocardial biopsy in 30 patients with primary amyloidosis and suspected cardiac involvement.Arch Intern Med19881486626663341867RAKyleRJSpencerDCDahlinValue of rectal biopsy in the diagnosis of primary systemic amyloidosis.Am J Med Sci19662515015065933764JGafniESoharRectal biopsy for the diagnosis of amyloidosis.Am J Med Sci196024033233613825900PWestermarkBStenkvistA new method for the diagnosis of systemic amyloidosis.Arch Intern Med19731325225234742405CALibbeyMSkinnerASCohenUse of abdominal fat tissue aspirate in the diagnosis of systemic amyloidosis.Arch Intern Med1983143154915526191729MADustonMSkinnerTShirahamaASCohenDiagnosis of amyloidosis by abdominal fat aspiration.Am J Med1987824124142435149JNBuxbaumEMGenegaPLazowskiInfiltrative nonamyloidotic monoclonal immunoglobulin light chain cardiomyopathy: an underappreciated manifestation of plasma cell dyscrasias.Cardiology20009322022811025347WLMillerRSWrightCGMcGregorTroponin levels in patients with amyloid cardiomyopathy undergoing cardiac transplantation.Am J Cardiol20018881381511589859GTakemuraYTakatsuKDoyamaExpression of atrial and brain natriuretic peptides and their genes in hearts of patients with cardiac amyloidosis.J Am Coll Cardiol199831754765MNordlingerBMagnaniMSkinnerRHFalkIs elevated plasma B-natriuretic peptide in amyloidosis simply a function of the presence of heart failure?Am J Cardiol20059698298416188528GPalladiniCCampanaCKlersySerum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.Circulation20031072440244512719281ADispenzieriRAKyleMAGertzSurvival in patients with primary systemic amyloidosis and raised serum cardiac troponins.Lancet20033611787178912781539BMurtaghSCHammillMAGertzRAKyleAJTajikMGroganElectrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement.Am J Cardiol20059553553715695149AGSiqueira-FilhoCLCunhaAJTajikJBSewardTSchattenbergERGiulianiM-mode and two-dimensional echocardiographic features in cardiac amyloidosis.Circulation1981631881967438392LCueto-GarciaGSReederRAKyleEchocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival.J Am Coll Cardiol198567377434031287CFPrestiBFWallerWFArmstrongCardiac amyloidosis mimicking the echocardiographic appearance of obstructive hypertrophic myopathy.Chest1988938818833349849SPSedlisJESaffitzVSSchwobASJaffeCardiac amyloidosis simulating hypertrophic cardiomyopathy.Am J Cardiol1984539699706538383RHFalkJFPlehnTDeeringSensitivity and specificity of the echocardiographic features of cardiac amyloidosis.Am J Cardiol1987594184222949593ALKleinLKHatleDJBurstowDoppler characterization of left ventricular diastolic function in cardiac amyloidosis.J Am Coll Cardiol198913101710262647814ALKleinLKHatleCPTaliercioSerial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis.J Am Coll Cardiol199016113511412229760JKoyamaPARay-SequinRHFalkLongitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis.Circulation20031072446245212743000TAWizenbergJMuzYHSohnWSamlowskiAMWeisslerValue of positive myocardial technetium-99m-pyrophosphate scintigraphy in the noninvasive diagnosis of cardiac amyloidosis.Am Heart J19821034684736278906RHFalkVWLeeARubinowWBHoodJrASCohenSensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloid.Am J Cardiol1983518268306299087MAGertzMLBrownMFHauserRAKyleUtility of technetium Tc 99m pyrophosphate bone scanning in cardiac amyloidosis.Arch Intern Med1987147103910443036031EPeruginiPLGuidalottiFSalviNoninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy.J Am Coll Cardiol2005461076108416168294RFattoriGRocchiFCellettiPBertacciniCRapezziGGavelliContribution of magnetic resonance imaging in the differential diagnosis of cardiac amyloidosis and symmetric hypertrophic cardiomyopathy.Am Heart J19981368248309812077AMMaceiraJJoshiSKPrasadCardiovascular magnetic resonance in cardiac amyloidosis.Circulation200511118619315630027FCellettiRFattoriGNapoliAssessment of restrictive cardiomyopathy of amyloid or idiopathic etiology by magnetic resonance imaging.Am J Cardiol19998379880110080445MAGertzRHFalkMSkinnerASCohenRAKyleWorsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents.Am J Cardiol198555(13) (pt 1)16454003314BEGriffithsPHughesRDowdleMRStephensCardiac amyloidosis with asymmetrical septal hypertrophy and deterioration after nifedipine.Thorax1982377117126891504ARubinowMSkinnerASCohenDigoxin sensitivity in amyloid cardiomyopathy.Circulation198163128512887014028JTCassidyCardiac amyloidosis: two cases with digitalis sensitivity.Ann Intern Med19615598999413877133GGregoratosJAbramsAEEpsteinACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices—summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines).J Am Coll Cardiol2002401703171912427427VMathewLJOlsonMAGertzDLHayesSymptomatic conduction system disease in cardiac amyloidosis.Am J Cardiol199780149114929399732MSkinnerJAndersonRSimmsTreatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.Am J Med19961002902988629674RAKyleMAGertzPRGreippA trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine.N Engl J Med1997336120212079110907RLComenzoEVosburghRWSimmsDose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients.Blood199688280128068839879MAGertzEBloodDHVesoleHMLazarusPRGreippAmyloidosis: a multicenter phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): an Eastern Cooperative Oncology Group Study.Bone Marrow Transplant20043414915415156165PMoreauVLeblondPBourquelotPrognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients.Br J Haematol19981017667699674753JDHosenpudTDeMarcoOHFrazierProgression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation: follow-up results of a multicenter survey.Circulation199184(5) (suppl III)III338III3431934428JKpodonuMGMassadACainesASGehaOutcome of heart transplantation in patients with amyloid cardiomyopathy.J Heart Lung Transplant2005241763176516297778SWDubreyMMBurkeAKhaghaniPNHawkinsMHYacoubNRBannerLong term results of heart transplantation in patients with amyloid heart disease.Heart20018520220711156673SWDubreyMMBurkePNHawkinsNRBannerCardiac transplantation for amyloid heart disease: the United Kingdom experience.J Heart Lung Transplant2004231142115315477107EARoseACGelijnsAJMoskowitzLong-term mechanical left ventricular assistance for end-stage heart failure.N Engl J Med20013451435144311794191GHolmgrenLSteenJEkstedtBiochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30).Clin Genet1991402422461685359GHerleniusHEWilczekMLarssonBGEriczonFamilial Amyloidotic Polyneuropathy World Transplant RegistryTen years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry.Transplantation200477647114724437WDLewisMSkinnerRWSimmsLAJonesASCohenRLJenkinsOrthotopic liver transplantation for familial amyloidotic polyneuropathy.Clin Transplant199481071108019018DAdamsDSamuelCGoulon-GoeauThe course and prognostic factors of familial amyloid polyneuropathy after liver transplantation.Brain2000123(pt 7)1495150410869060PRBergethonTDSabinDLewisRWSimmsASCohenMSkinnerImprovement in the polyneuropathy associated with familial amyloid polyneuropathy after liver transplantation.Neurology1996479449518857724PParrillaPRamirezLFAndreuLong-term results of liver transplantation in familial amyloidotic polyneuropathy type I.Transplantation1997646466499293880BNardoPBeltempoRBertelliCombined heart and liver transplantation in four adults with familial amyloidosis: experience of a single center.Transplant Proc20043664564715110620EJonsenOBSuhrKTashimaEAthlinEarly liver transplantation is essential for familial amyloidotic polyneuropathy patients' quality of life.Amyloid20018525711293825
TI - Amyloidosis and the Heart
JF - JAMA Internal Medicine
DO - 10.1001/archinte.166.17.1805
DA - 2006-09-25
UR - https://www.deepdyve.com/lp/american-medical-association/amyloidosis-and-the-heart-0dmtErpnVt
SP - 1805
EP - 1813
VL - 166
IS - 17
DP - DeepDyve
ER -